Illumina, Inc. $ILMN Position Boosted by Citigroup Inc.

Citigroup Inc. raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,103 shares of the life sciences company’s stock after acquiring an additional 12,649 shares during the period. Citigroup Inc. owned approximately 0.11% of Illumina worth $15,870,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC grew its position in Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after buying an additional 1,174,295 shares in the last quarter. Edmond DE Rothschild Holding S.A. increased its stake in shares of Illumina by 140.1% during the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock valued at $136,312,000 after acquiring an additional 833,750 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Illumina by 1,558.0% during the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock valued at $69,528,000 after acquiring an additional 684,802 shares during the period. Pacer Advisors Inc. acquired a new stake in Illumina in the third quarter worth approximately $61,663,000. Finally, Invesco Ltd. lifted its position in Illumina by 48.9% in the second quarter. Invesco Ltd. now owns 1,353,077 shares of the life sciences company’s stock worth $129,097,000 after purchasing an additional 444,543 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. This represents a 12.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.60% of the stock is currently owned by insiders.

Illumina Stock Performance

Illumina stock opened at $134.46 on Friday. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The firm’s 50 day simple moving average is $135.12 and its 200-day simple moving average is $118.11. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The company has a market cap of $20.56 billion, a P/E ratio of 24.67, a price-to-earnings-growth ratio of 2.44 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter last year, the business posted $0.95 EPS. The company’s revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ILMN. Guggenheim boosted their price objective on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Stifel Nicolaus raised their price objective on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Robert W. Baird set a $137.00 price objective on shares of Illumina in a research note on Friday, February 6th. Finally, Evercore set a $150.00 target price on shares of Illumina in a research note on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $129.69.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Launched TruPath Genome and unveiled a NovaSeq X roadmap at AGBT — new product roadmap and platform upgrades can drive future instrument sales and recurring consumable revenue, and management highlighted multiomics/cancer initiatives that improve long‑term growth visibility. Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
• Positive Sentiment: Illumina Laboratory Services to provide clinical whole‑genome sequencing and interpretation to Florida State University’s pediatric rare disease lab — expands clinical lab services, supports adoption of clinical WGS, and helps generate recurring service revenue. Illumina whole‑genome sequencing technology to accelerate rare disease testing in Florida
• Positive Sentiment: Collaboration with Takara Bio on a single‑cell spatial transcriptomics workflow presented at AGBT — strengthens Illumina’s single‑cell and spatial offerings and complements the company’s multiomics strategy. Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow
• Positive Sentiment: Market/flow-driven momentum: analysts and quant flows have turned more constructive after Illumina’s upbeat 2026 outlook and the completed SomaLogic deal — higher relative strength and above‑average volume are cited as drivers of today’s rally. Illumina jumps 5.5% as momentum builds after upbeat outlook and multiomics push
• Neutral Sentiment: Canaccord reiterated a Hold, noting competitive pressures but that 2026 revenue targets remain intact — keeps near‑term expectations cautious despite longer‑term roadmap. Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating
• Neutral Sentiment: Competitive context: comparisons to fast‑growing peers (e.g., Tempus) highlight execution risk and the need for Illumina to convert product and multiomics momentum into sustained top‑line growth. TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
• Neutral Sentiment: Short‑interest data released today shows zero reported short shares (likely a reporting anomaly) and thus offers no clear bearish pressure signal at present.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.